Morgan Stanley initiates Onto Innovation stock with overweight rating

Morgan Stanley initiated Onto Innovation with an Overweight rating and a $371 price target, implying about 15% upside from the $323.88 share price. The firm expects Onto’s advanced node revenue to grow 30% in 2026 and 39% in 2027, while Specialty Device and Advanced Packaging revenue is projected to rise 46% in 2026 and 38% in 2027. Gross margin is forecast to expand from 54.6% in 2025 to 58.0% in 2027, supported by Dragonfly G5 and Semilab-related growth, though the stock has also priced a $1.3 billion convertible note offering.

Analysis

ONTO is being rerated less on near-term earnings and more on mix shift durability: advanced node plus advanced packaging can compound faster than legacy WFE cycles, and that matters because process-control tools tend to have stickier attach rates and better gross margin leverage than the broader equipment basket. The key second-order effect is that every incremental dollar of front-end and packaging revenue should carry disproportionate operating leverage into 2026-27, which can make ONTO look like a quality-growth compounder rather than a cyclical equipment name.

The new debt financing is a signal that management is trying to pre-fund optionality rather than merely defend the balance sheet. A zero-coupon convert at a high strike effectively monetizes equity upside while lowering cash interest burden, which is usually accretive if the stock can keep trending higher into the conversion window; the flip side is capped near-term upside if dealers hedge aggressively around the issue size. That creates a more nuanced setup: stock can grind higher on estimate revisions, but the convert overhang may mute momentum if valuation gets stretched before fundamental proof points arrive.

Consensus may be underestimating how much of the upside is already embedded in the gross margin path. If gross margin expansion stalls even modestly, the multiple premium collapses quickly because the market is paying for an eventual 58%+ margin profile, not just revenue growth. Conversely, the biggest hidden beneficiary may be ONTO's downstream customers in advanced packaging: if Dragonfly adoption is real, it signals that packaging inspection is becoming a gating item in AI and HBM scaling, which can pull forward capex decisions across the ecosystem.

The contrarian risk is that this is a crowded quality-growth story with cyclicality masked by secular language. If semi capex broadens but pricing normalizes, ONTO could still miss the implied growth spread versus WFE, and the stock would likely de-rate before 2027 numbers matter. Near term, the convertible pricing creates a technical anchor around the low-to-mid $300s, but over the next 6-12 months the trade is still fundamentally driven by whether customers keep buying premium inspection tools into a softer macro tape.

Key Decisions for Investors

• Go long ONTO on pullbacks toward the convert-induced technical floor; target a 6-12 month move toward $360-$380 if advanced packaging adoption and estimate revisions persist, with a stop if gross margin guidance inflects below the high-50s trajectory.
• Sell upside calls against a long ONTO core position for the next 1-2 quarters; the convert and already-lofty expectations make covered-call premium attractive while limiting exposure to near-term multiple compression.
• Pair trade: long ONTO / short a lower-margin WFE equipment name over 6-12 months; the thesis is margin-mix outperformance and superior EPS revision momentum, with ONTO benefiting if advanced packaging spending stays resilient while broader WFE moderates.
• Use a tight risk collar around the convertible event window; if dealer hedging suppresses upside post-issuance, reassess after the next two earnings prints rather than paying up into a potentially crowded quality factor trade.
• For more aggressive exposure, buy 9-12 month ONTO calls struck near the conversion price only on weakness; risk/reward improves if the stock re-rates through the high-$300s, but premium decay is the main hazard if the stock consolidates.